gamma-aminobutyric acid has been researched along with Phobic Disorders in 23 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Phobic Disorders: Anxiety disorders in which the essential feature is persistent and irrational fear of a specific object, activity, or situation that the individual feels compelled to avoid. The individual recognizes the fear as excessive or unreasonable.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Further studies are required to confirm this effect and to determine whether a dose-response relationship exists." | 2.69 | Treatment of social phobia with gabapentin: a placebo-controlled study. ( Davidson, JR; Greist, JH; Janney, CA; Jefferson, JW; Katzelnick, DJ; Pande, AC; Sutherland, SM; Weisler, RH, 1999) |
| "Pharmacologic treatments for panic disorder and social phobia have been available since the early 1960s." | 2.40 | Panic disorder and social phobia: current treatments and new strategies. ( Connor, KM; Davidson, JR; Sutherland, SM, 1998) |
| "Excessive sweating (hyperhidrosis) is an overlooked and potentially disabling symptom, which is often seen in social anxiety disorder (SAD)." | 1.31 | Hyperhidrosis in social anxiety disorder. ( Churchill, LE; Connor, KM; Davidson, JR; Foa, EB, 2002) |
| "We conclude that hyperhidrosis is frequently seen in patients with SAD, and that its response to treatment is variable." | 1.31 | Hyperhidrosis in social anxiety disorder. ( Churchill, LE; Connor, KM; Davidson, JR; Foa, EB, 2002) |
| "Hyperhidrosis was found in 24." | 1.31 | Hyperhidrosis in social anxiety disorder. ( Churchill, LE; Connor, KM; Davidson, JR; Foa, EB, 2002) |
| "Amphetamine, 1 mg/kg, was then combined with ineffective doses of GAG and progabide (50 and 100 mg/kg, respectively)." | 1.30 | Interactions between dopamine and GABA in the control of ambulatory activity and neophobia in the mouse. ( Agmo, A; Belzung, C, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.35) | 18.7374 |
| 1990's | 6 (26.09) | 18.2507 |
| 2000's | 12 (52.17) | 29.6817 |
| 2010's | 4 (17.39) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kawalec, P | 1 |
| Cierniak, A | 1 |
| Pilc, A | 1 |
| Nowak, G | 1 |
| Chutko, LS | 2 |
| Surushkina, SIu | 1 |
| Iakovenko, EA | 1 |
| Nikishena, IS | 1 |
| Anisimova, TI | 2 |
| Bondarchuk, IuL | 1 |
| Surushkina, SY | 1 |
| Greist, JH | 2 |
| Liu-Dumaw, M | 1 |
| Schweizer, E | 1 |
| Feltner, D | 1 |
| Davidson, JR | 4 |
| Foa, EB | 1 |
| Connor, KM | 3 |
| Churchill, LE | 1 |
| Blanco, C | 1 |
| Schneier, FR | 1 |
| Schmidt, A | 1 |
| Blanco-Jerez, CR | 1 |
| Marshall, RD | 1 |
| Sánchez-Lacay, A | 1 |
| Liebowitz, MR | 1 |
| Pigott, TA | 1 |
| Ameli, R | 1 |
| Snow, J | 1 |
| Rakocevic, G | 1 |
| Dalakas, MC | 1 |
| Abdou, AM | 1 |
| Higashiguchi, S | 1 |
| Horie, K | 1 |
| Kim, M | 1 |
| Hatta, H | 1 |
| Yokogoshi, H | 1 |
| Biermann, T | 1 |
| Bleich, S | 1 |
| Kornhuber, J | 1 |
| Hillemacher, T | 1 |
| Agmo, A | 1 |
| Belzung, C | 1 |
| Pollack, MH | 1 |
| Matthews, J | 1 |
| Scott, EL | 1 |
| Pande, AC | 1 |
| Jefferson, JW | 2 |
| Janney, CA | 1 |
| Katzelnick, DJ | 1 |
| Weisler, RH | 1 |
| Sutherland, SM | 2 |
| Sutherland, S | 1 |
| Weisler, R | 1 |
| van Ameringen, M | 1 |
| Mancini, C | 1 |
| Farvolden, P | 1 |
| Oakman, J | 1 |
| Li, D | 1 |
| Chokka, P | 1 |
| Tibbo, P | 1 |
| Argyropoulos, SV | 1 |
| Bell, CJ | 1 |
| Nutt, DJ | 1 |
| Durkin, JP | 1 |
| Hoehn-Saric, R | 1 |
| McLeod, DR | 1 |
10 reviews available for gamma-aminobutyric acid and Phobic Disorders
| Article | Year |
|---|---|
Pregabalin for the treatment of social anxiety disorder.
Topics: Anti-Anxiety Agents; gamma-Aminobutyric Acid; Humans; Phobic Disorders; Pregabalin; Quality of Life; | 2015 |
[Anxiety and fear in children and adolescents].
Topics: Adolescent; Child; Fear; Female; gamma-Aminobutyric Acid; Humans; Male; Phobic Disorders; Tranquiliz | 2016 |
Pharmacological treatment of social anxiety disorder: a meta-analysis.
Topics: Acetates; Amines; Anti-Anxiety Agents; Antidepressive Agents; Antimanic Agents; Anxiety Disorders; C | 2003 |
Anxiety disorders in women.
Topics: Agoraphobia; Anti-Anxiety Agents; Anxiety Disorders; Comorbidity; Female; gamma-Aminobutyric Acid; H | 2003 |
Social phobia: issues in assessment and management.
Topics: Acetates; Amines; Anticonvulsants; Benzodiazepines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-A | 1999 |
Drugs in development for social anxiety disorder: more to social anxiety than meets the SSRI.
Topics: Animals; Anxiety Disorders; Dopamine; gamma-Aminobutyric Acid; Humans; Monoamine Oxidase Inhibitors; | 2000 |
Toward an integrative understanding of social phobia.
Topics: Animals; Brain; Disease Models, Animal; gamma-Aminobutyric Acid; Genetic Predisposition to Disease; | 2001 |
Brain function in social anxiety disorder.
Topics: Anxiety; Anxiety Disorders; Brain; Dopamine; gamma-Aminobutyric Acid; Human Growth Hormone; Humans; | 2001 |
Panic disorder and social phobia: current treatments and new strategies.
Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Cost-Benefit Analysis; Cycl | 1998 |
Generalized anxiety disorder.
Topics: Adrenergic beta-Antagonists; Alprazolam; Animals; Anti-Anxiety Agents; Antidepressive Agents, Tricyc | 1985 |
3 trials available for gamma-aminobutyric acid and Phobic Disorders
| Article | Year |
|---|---|
Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Follow-Up Studies; gamma-Aminobutyric Acid; Hu | 2011 |
Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans.
Topics: Administration, Oral; Adult; Anxiety; Electroencephalography; Female; GABA Agents; gamma-Aminobutyri | 2006 |
Treatment of social phobia with gabapentin: a placebo-controlled study.
Topics: Acetates; Adult; Amines; Anti-Anxiety Agents; Cyclohexanecarboxylic Acids; Double-Blind Method; Fema | 1999 |
10 other studies available for gamma-aminobutyric acid and Phobic Disorders
| Article | Year |
|---|---|
[Cognitive and emotional impairments in patients with protracted anxiety-phobic disorders].
Topics: Acute Disease; Adolescent; Adult; Chronic Disease; Cognition Disorders; gamma-Aminobutyric Acid; Hum | 2014 |
Hyperhidrosis in social anxiety disorder.
Topics: Acetates; Adult; Amines; Calcium Channel Blockers; Clinical Trials as Topic; Clonazepam; Cognitive B | 2002 |
A neuropsychological assessment of phobias in patients with stiff person syndrome.
Topics: Accidental Falls; Adult; Anxiety Disorders; Brain; Brain Chemistry; Cognition Disorders; Female; gam | 2005 |
Pregabalin: new indication. Generalised anxiety: better to use benzodiazepine.
Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Anxiety; Benzodiazepines; Clinical Trials as Topic; Dru | 2007 |
Pregabalin in benzodiazepine withdrawal.
Topics: Adult; Alprazolam; Anticonvulsants; Anxiety Disorders; gamma-Aminobutyric Acid; Humans; Hypnotics an | 2007 |
Interactions between dopamine and GABA in the control of ambulatory activity and neophobia in the mouse.
Topics: Amphetamine; Animals; Chi-Square Distribution; Dopamine; Dopamine Agents; Exploratory Behavior; GABA | 1998 |
Gabapentin as a potential treatment for anxiety disorders.
Topics: Acetates; Adult; Alprazolam; Amines; Anticonvulsants; Anxiety Disorders; Cyclohexanecarboxylic Acids | 1998 |
Gabapentin. CI 945, GOE 3450, Neurontin.
Topics: Acetates; Adult; Amines; Anticonvulsants; Area Under Curve; Biological Availability; Child; Child, P | 1999 |
Benzodiazepines and anticonvulsants for social phobia (social anxiety disorder).
Topics: Acetates; Alprazolam; Amines; Anticonvulsants; Benzodiazepines; Clinical Trials as Topic; Clonazepam | 2001 |
Gabapentin in complicated school refusal.
Topics: Acetates; Adolescent; Amines; Comorbidity; Cyclohexanecarboxylic Acids; Cyclohexanols; Drug Therapy, | 2002 |